<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891016</url>
  </required_header>
  <id_info>
    <org_study_id>HenanCH immunotherapy006</org_study_id>
    <nct_id>NCT04891016</nct_id>
  </id_info>
  <brief_title>Toripalimab Plus FLOT in Locally Advanced Gastric Cancer</brief_title>
  <official_title>Toripalimab Combined With FLOT Regimen in Locally Advanced Gastric cancer-a Prospective, Open, Single-center, Phase Ⅱ Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neoadjuvant therapy for locally advanced gastric cancer is still in the exploratory stage.&#xD;
      With the emergence of immune checkpoint inhibitors, neoadjuvant chemoimmunotherapy is also in&#xD;
      the exploratory stage in locally advanced gastric cancer. At present, chemotherapy combined&#xD;
      with immunotherapy is usually a simple combination of chemotherapeutic drugs and immune&#xD;
      drugs, without taking into account of the influenece of applied sequence. The purpose of this&#xD;
      study is to explore whether the sequence of chemotherapy and immunotherapy influence the&#xD;
      complete pathological response rate in locally advanced gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 12, 2021</start_date>
  <completion_date type="Anticipated">May 11, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 11, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>patients were randomized at 1:1 into experiment group and control group. In control group patients received chemotherapy and toripalimab on same day, in experiment group patients received chemotherapy on day 1 and toripalimab on day 3.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete response rate</measure>
    <time_frame>6 months</time_frame>
    <description>the proportion of patients with no tumor cells in the postoperative specimens</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>rate of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>the rate of patients who keep from disease at three years</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Chemotherapy</condition>
  <condition>Immune Checkpoint Inhibitor</condition>
  <condition>Locally Advanced Gastric Carcinoma</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients received FLOT regimen on day 1 and toripalimab on day 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients received FLOT regimen and toripalimab on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>delayed toripalimab</intervention_name>
    <description>chemotherapy plus toripalimab and toripalimab was delayed on day 3</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control</intervention_name>
    <description>chemotherapy and toripalimab were given on same day</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  70 ≥ Age ≥ 18 years regardless of gender&#xD;
&#xD;
          -  Gastric adenocarcinoma confirmed by pathology&#xD;
&#xD;
          -  no distant metastasis and resectable or potentially resectable evaluated by general&#xD;
             surgery experts&#xD;
&#xD;
          -  ECOG PS 0-1&#xD;
&#xD;
          -  clinical stage III by AJCC 8.0&#xD;
&#xD;
          -  expected lifespan over 3 months&#xD;
&#xD;
          -  Adequate organ function: 1) without growth factor and blood component support in the&#xD;
             first 2 weeks of enrollment; 2) Cardiac function: no heart disease or coronary heart&#xD;
             disease, grade 1-2; 3) liver function: TBIL ≤ 2ULN, AST ≤ 2.5 ULN, alt ≤ 2.5 ULNX 4&#xD;
             Renal function: cr ≤ 1.25ULN, liver function: TBIL ≤ 2ULN, TBIL ≤ 2.5ULN, alt ≤&#xD;
             2.5ULN, 4)renal function: cr ≤ 1.25ULN.&#xD;
&#xD;
          -  blood pressure normal or controlled within the normal range by antihypertensive drugs&#xD;
&#xD;
          -  Diabetic patients were treated with hypoglycemic drugs to control fasting blood&#xD;
             glucose ≤ 8mmol/L&#xD;
&#xD;
          -  Patients with positive hepatitis B surface antigen need to be tested for quantitative&#xD;
             detection of hepatitis B DNA virus. HBV DNA should be less than the upper limit of the&#xD;
             normal test value for patients with HBV infection.&#xD;
&#xD;
          -  no other serious diseases conflicting with this study&#xD;
&#xD;
          -  No history of other malignant tumors&#xD;
&#xD;
          -  Women of childbearing age must be tested negative for blood pregnancy test within 7&#xD;
             days before enrollment, and subjects of childbearing age must use appropriate&#xD;
             contraceptive measures during the trial and within 6 months after the trial&#xD;
&#xD;
          -  agreement to participate in this study and signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Suffered from severe infectious diseases within 4 weeks before entering the group&#xD;
&#xD;
          -  Bronchial asthma requires intermittent use of bronchodilators or medical intervention&#xD;
&#xD;
          -  Due to the use of immunosuppressants before coexisting diseases and the dosage of&#xD;
             immunosuppressants ≥ 10mg/, the oral dose of prednisone lasted for more than 2 weeks&#xD;
&#xD;
          -  Clinically obvious cardio-cerebrovascular diseases, including, but not limited to,&#xD;
             severe acute myocardial infarction, instability or severe angina pectoris, coronary&#xD;
             artery bypass surgery, congestive heart failure, ventricular arrhythmias requiring&#xD;
             medical intervention, left ventricular ejection fraction &lt; 50%, stroke within 6 months&#xD;
&#xD;
          -  Allergic to any experimental drug and its excipients, or have a history of severe&#xD;
             allergy, or are contraindications to experimental drugs&#xD;
&#xD;
          -  Severe mental disorders&#xD;
&#xD;
          -  Abnormal coagulation function (PT &gt; 16s, APTT &gt; 53s, TT &gt; 21s Fib &lt; 1.5g/L), bleeding&#xD;
             tendency or undergoing thrombolysis or anticoagulation therapy&#xD;
&#xD;
          -  Past or present pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation&#xD;
             pneumonia, severe impairment of lung function, etc.&#xD;
&#xD;
          -  Unable to swallow research drugs, chronic diarrhea (including but not limited to&#xD;
             irritable bowel syndrome, Crohn's disease, ulcerative colitis) and intestinal&#xD;
             obstruction affect drug use and absorption&#xD;
&#xD;
          -  Have a history of immunodeficiency, including positive for HIV, or suffer from other&#xD;
             acquired, congenital immunodeficiency diseases, or have a history of organ transplant&#xD;
&#xD;
          -  Other researchers evaluate those who do not meet the criteria for admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quanli Gao, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Immunotherapy, Henan Provincial Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quanli Gao, M.D</last_name>
    <phone>+8637165587483</phone>
    <email>gaoquanli2015@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lingdi Zhao, M.D</last_name>
    <phone>+8637165587483</phone>
    <email>lingdizhao@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Affiliated Cancer Hospital of Zhengzhou University &amp; Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13. Erratum in: Nat Med. 2019 Jun 17;:.</citation>
    <PMID>31086347</PMID>
  </reference>
  <reference>
    <citation>Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019 Aug 1;30(8):1279-1288. doi: 10.1093/annonc/mdz158.</citation>
    <PMID>31095287</PMID>
  </reference>
  <reference>
    <citation>He X, Du Y, Wang Z, Wang X, Duan J, Wan R, Xu J, Zhang P, Wang D, Tian Y, Han J, Fei K, Bai H, Tian J, Wang J. Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma. J Immunother Cancer. 2020 Oct;8(2). pii: e000807. doi: 10.1136/jitc-2020-000807.</citation>
    <PMID>33115941</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Quanli Gao</investigator_full_name>
    <investigator_title>Head of immunotherapy department, Clinical professor, Leader of immunotherapy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Demographic characteristics, adverse reactions, postoperative pathology</ipd_description>
    <ipd_time_frame>every 6 months</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

